Oppenheimer analyst Kevin DeGeeter, after speaking with management, continues to expect Invitae to provide Q4 revenue and 2020 guidance in mid-January. He believes 2020 offers Invitae "multiple avenues" for a growth rate "significantly above nearly all other publicly traded diagnostic companies." However, there is limited visibility on the pace of adoption curve or rate of market expansion, DeGeeter tells investors in a research note. As such, the analyst believes that if management provides 2020 guidance based on growth drivers with clearly established markets, which is their traditional approach, his $364.9M 2020 revenue estimate has downside risk. The analyst is above the consensus at $333.5M. DeGeeter keeps an Outperform rating on Invitae with a $34 price target. He believes such "conservative" guidance would have "paths to material upside."